J M Calvo-Romero1, J L Ramos-Salado. 1. Servicio de Medicina Interna, Hospital Regional Universitario Infanta Cristina, Badajoz, España.
Abstract
INTRODUCTION: Donepezil is a drug which is being used more and more widely in mild-moderate Alzheimer's disease. In general, it is well tolerated and the side-effects are basically cholinergic-dependent. Symptomatic disorders of cardiac rhythm associated with the use of donepezil are extremely unusual. CLINICAL CASE: We describe the case of an 81 year old patient with hypertensive cardiopathy, who developed sinus bradycardia, fainting and left cardiac failure three weeks after starting treatment with donepezil. When donepezil was stopped the sinus bradycardia disappeared, a 24 hour electrocardiographic holter showed no signs of sinus node disease and no episodes of this type occurred during the following six months. CONCLUSION: Symptomatic sinus bradycardia is a possible adverse effect of treatment with donepezil in Alzheimer's disease.
INTRODUCTION:Donepezil is a drug which is being used more and more widely in mild-moderate Alzheimer's disease. In general, it is well tolerated and the side-effects are basically cholinergic-dependent. Symptomatic disorders of cardiac rhythm associated with the use of donepezil are extremely unusual. CLINICAL CASE: We describe the case of an 81 year old patient with hypertensive cardiopathy, who developed sinus bradycardia, fainting and left cardiac failure three weeks after starting treatment with donepezil. When donepezil was stopped the sinus bradycardia disappeared, a 24 hour electrocardiographic holter showed no signs of sinus node disease and no episodes of this type occurred during the following six months. CONCLUSION: Symptomatic sinus bradycardia is a possible adverse effect of treatment with donepezil in Alzheimer's disease.
Authors: Michael H Rosenbloom; Richard Finley; Melvin M Scheinman; Mitchell D Feldman; Bruce L Miller; Gil D Rabinovici Journal: Alzheimer Dis Assoc Disord Date: 2010 Apr-Jun Impact factor: 2.703
Authors: Laura Y Park-Wyllie; Muhammad M Mamdani; Ping Li; Sudeep S Gill; Andreas Laupacis; David N Juurlink Journal: PLoS Med Date: 2009-09-29 Impact factor: 11.069